Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Lonza, Agennix Ink Deal For Production Of Talactoferrin - Quick Facts

Lonza Group AG (LZAGF.PK) said it entered into an agreement with Agennix AG for the production of Agennix's first-in-class oral Dendritic Cell Mediated Immunotherapy, talactoferrin, currently in Phase III testing for the treatment of non-small cell lung cancer.

As per the agreement, Lonza will produce commercial material at its microbial manufacturing facility in Kourim, Czech Republic. Lonza stated that the agreement initiates the process needed to be able to ultimately seek approval for Lonza as a second manufacturer of talactoferrin after the initial commercial launch.

Rajesh Malik, chief medical officer and Management Board member of Agennix, said, "We are pleased to enter this agreement with Lonza, which has extensive experience manufacturing biologics on a commercial scale. In anticipation of positive Phase III data and a potential product approval, it is important that we have more than one manufacturer in place to ensure we can meet anticipated commercial demand and that we have security of supply."

Click here to receive FREE breaking news email alerts for Lonza Group and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Swiss drug maker Roche Holding said a late-stage trial of its breast cancer drug Kadcyla did not provide superior results compared with an existing therapy. FCA US, until recently known as Chrysler, said Friday it is recalling 257,000 Dodge Ram pickups. The auto maker says the rear axle pinion nut on certain model year 2005 Dodge Ram 1500 trucks may loosen due to an undersized spline on the pinion gear. If the pinion nut loosens, the rear axle may... This medical device company has a very impressive track record of growing business over the past decade. increasing sales from $490.2 million in 2004 to $1.72 billion this year. The Silicone Hydrogel daily disposable lens portfolio constitutes a major avenue for growth.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.